High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics.

CONTEXT Reduced high density lipoprotein (HDL) concentration in the metabolic syndrome (MetS) is associated with increased risk of diabetes and cardiovascular disease and is related to defects in the kinetics of HDL apolipoprotein (apo) A-I and A-II. OBJECTIVE The objective of the study was to investigate HDL apoA-I and apoA-II kinetics in nondiabetic men with MetS and lean controls by developing a model that describes the kinetics of lipoprotein (Lp)A-I and LpA-I:A-II particles. DESIGN Twenty-three MetS men and 10 age-matched lean controls were investigated. ApoA-I and apoA-II tracer/tracee ratios were studied after iv d3-leucine administration using gas chromatography mass spectrometry. RESULTS Compared with lean subjects, MetS subjects had accelerated catabolism of LpA-I (P < 0.001), LpA-I:A-II (P = 0.005), and apoA-II (P = 0.005); the production rate of LpA-I was also significantly elevated in MetS, so that the dominant changes in plasma concentrations were reduction in LpA-I:A-II (P < 0.001) and apoA-II (P < 0.05). Increased catabolism of LpA-I and LpA-I:A-II was directly related to increased waist circumference, hypertriglyceridemia, low HDL-cholesterol, small HDL particle size, hyperinsulinemia, and low phospholipid transfer protein (PLTP) activity; overproduction of LpA-I was significantly associated with increased waist circumference, insulin resistance, and low PLTP activity. CONCLUSIONS MetS men exhibit hypercatabolism of the two major HDL lipoprotein particles, LpA-I and LpA-I:A-II, but selective overproduction of LpA-I maintains a normal plasma concentration of LpA-I. These kinetic perturbations are probably related to central obesity, insulin resistance, hypertriglyceridemia, and low plasma PLTP activity.

[1]  A. von Eckardstein,et al.  High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[2]  D. Rader,et al.  In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I,A-II. , 1991, Journal of lipid research.

[3]  J. Albers,et al.  Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. , 1982, Journal of lipid research.

[4]  A. Evans,et al.  Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[5]  P. Barter,et al.  Formation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[6]  R. Dullaart,et al.  Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins , 2003, European journal of clinical investigation.

[7]  P. Barter,et al.  Antiinflammatory Properties of HDL , 2004 .

[8]  T. Ohta,et al.  Studies on the lipid and apolipoprotein compositions of two species of apoA-I-containing lipoproteins in normolipidemic males and females. , 1988, Journal of lipid research.

[9]  A. Tall,et al.  Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. , 2000, Journal of lipid research.

[10]  H. Brewer,et al.  Metabolism of human apolipoproteins A-I and A-II: compartmental models. , 1983, Journal of lipid research.

[11]  M. Taskinen,et al.  HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. , 1995, Circulation.

[12]  G. Watts,et al.  Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. , 2003, Diabetes.

[13]  J. Ordovás,et al.  Metabolism of apolipoproteins A-I, A-II, and A-IV. , 1986, Methods in enzymology.

[14]  A. von Eckardstein,et al.  Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[15]  D. Rader,et al.  Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[16]  J. Fruchart,et al.  Apolipoprotein A-II, HDL metabolism and atherosclerosis. , 2002, Atherosclerosis.

[17]  J. Ordovás,et al.  Impact of gender on the metabolism of apolipoprotein A-I in HDL subclasses LpAI and LpAI:AII in older subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[18]  A. Van der Laarse,et al.  Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. , 2003, Journal of lipid research.

[19]  P. Barter.  Metabolic abnormalities: high-density lipoproteins. , 2004, Endocrinology and metabolism clinics of North America.

[20]  J. Fruchart,et al.  Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. , 1990, Clinical chemistry.

[21]  P. Thompson,et al.  High-density apolipoprotein A-I and A-II kinetics in relation to regional adiposity. , 1992, Metabolism: clinical and experimental.

[22]  S. Eisenberg,et al.  Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. , 1989, The Journal of clinical investigation.

[23]  S. Eisenberg,et al.  Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  M. Cnop,et al.  Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex , 2003, Diabetologia.

[25]  G. Luc,et al.  Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator–Activated Receptor &agr; Modulation , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Taskinen,et al.  Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. , 1996, Atherosclerosis.

[27]  P. Gambert,et al.  Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. , 2000, Atherosclerosis.

[28]  R. Stocker,et al.  Oxidation of High Density Lipoproteins , 1998, The Journal of Biological Chemistry.

[29]  A. Tol.  Phospholipid transfer protein. , 2002 .

[30]  E. Ford.  Prevalence of the metabolic syndrome in US populations. , 2004, Endocrinology and metabolism clinics of North America.

[31]  B. Paulweber,et al.  Influence of obesity and insulin sensitivity on phospholipid transfer protein activity , 2001, Diabetologia.

[32]  B. Staels,et al.  Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis , 1999 .

[33]  D. Rader,et al.  New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport , 2005, Circulation research.

[34]  I. Goldberg,et al.  Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. , 1993, The Journal of clinical investigation.

[35]  M. Hanefeld,et al.  In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. , 1998, Diabetes.

[36]  M. Jauhiainen,et al.  ApoA-II/apoA-I molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion. , 1997, Journal of lipid research.

[37]  Anthony Gamst,et al.  Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey , 2004, Circulation.

[38]  Z. Vajo,et al.  Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. , 2002, Atherosclerosis.

[39]  M. Krempf,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society In Vivo Evidence for the Role of Lipoprotein Lipase Activity in the Regulation of Apolipoprotein AI Metabolism: A Kinetic Study in Control Subje , 2022 .